Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Influence of PCSK9 polymorphisms on plasma lipids and response to atorvastatin treatment in Brazilian subjects.

Journal of clinical lipidology - 1 Jan 2000

Anderson Jacqueline M, Cerda Alvaro, Hirata Mario H, Rodrigues Alice C, Dorea Egidio L, Bernik Marcia M S, Bertolami Marcelo C, Faludi Andre A, Hirata Rosario D C

Abstract excerpt

BACKGROUND: The proprotein convertase subtilisin/kexin type 9 (PCSK9) has a key role in the regulation of plasma low-density lipoprotein (LDL) cholesterol by enhancing the degradation of LDL receptor. Functional variants in PCSK9 have been associated with differences in plasma lipids and may contribute to the variability of the response to cholesterol-lowering drugs. OBJECTIVE: To investigate the influence of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Atorvastatin
Share to Biomarkers, Pharmacological

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cholesterol, LDL

Share to Heptanoic Acids

Share to Hypercholesterolemia

Share to Proprotein Convertase 9

Share to Proprotein Convertases

Share to Pyrroles

Source

Identifiers

PMID: 24793346
DOI: 10.1016/j.jacl.2014.02.008

Genes

PCSK9

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Influence of PCSK9 polymorphisms on plasma lipids and response to atorvastatin treatment in Brazilian subjects.PMID 24793346Read ↗

PCSK9 and Lipid Metabolism: Genetic Variants, Current Therapies, and Cardiovascular Outcomes.Semantic proximity Read ↗

The influence of PCSK9 polymorphisms on serum low-density lipoprotein cholesterol and risk of atherosclerosis.Semantic proximity Read ↗

Evaluation of PCSK9 levels and its genetic polymorphisms in women with polycystic ovary syndrome.Semantic proximity Read ↗

Clinical aspects of PCSK9.Semantic proximity Read ↗

PCSK9 Variants in Familial Hypercholesterolemia: A Comprehensive SynopsisSemantic proximity Read ↗

Serum PCSK9 levels, but not PCSK9 polymorphisms, are associated with CAD risk and lipid profiles in southern Chinese Han population.Semantic proximity Read ↗

Genome-wide association of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) plasma levels in the ELSA-Brasil studySemantic proximity Read ↗

PCSK9 gene mutations and low-density lipoprotein cholesterol.Semantic proximity Read ↗

LDL-cholesterol and PCSK9 in patients with familial hypercholesterolemia: influence of PCSK9 variants under lipid-lowering therapy.Semantic proximity Read ↗

Genetic Regulation of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Plasma Levels and Its Impact on Atherosclerotic Vascular Disease Phenotypes.Semantic proximity Read ↗

Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease.Semantic proximity Read ↗

The effect of genetic variation in PCSK9 on the LDL-cholesterol response to statin therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.